Prot #AP-PA02-101: A Phase 1b/2a, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AP-PA02 Multi-Phage Therapeutic Candidate for Inhalation in Subjects with Cys

Project: Research project

Project Details

StatusFinished
Effective start/end date2/2/212/2/24

Funding

  • Armata Pharmaceuticals, Inc. ((OE) Prot #AP-PA02-101)